ENTITY
GNI Group

GNI Group (2160 JP)

6
Analysis
Health CareJapan
GNI Group Ltd. develops therapeutic pharmaceutical products utilizing Genome analysis. The Company targets diseases indigenous to Asian countries. GNI controls the whole process of drug discovery by conducting clinical trials, research and development, and marketing. The Company owns global subsidiaries in China and the US.
more
Refresh
bullishMercari
28 Nov 2021 18:56

TOPIX Inclusions: Who Is READY? 4.0

In this insight, we take a look at potential pre-event candidates who could move to the First Section of the Tokyo Stock Exchange in the next few...

Share
20 Jun 2024 12:39

TOPIX Market Consultation: Wider Next-Gen Universe in a Couple of Years; But Stocks Moving Already

JPX has commenced a market consultation that could result in 38 adds and 447 deletions for the index in Oct 2026. There are a lot of high impact...

Logo
472 Views
Share
28 Dec 2018 17:53

Japan Pharma - Top Picks (28 Dec 2018)

                                                                                                                                                   ...

18 Dec 2018 14:43

Japan Pharma - Top Picks

While Gni Group Ltd (2160 JP) is our high risk-high return pick, Mitsubishi Tanabe Pharma (4508 JP)  is a contrarian call in anticipation of value...

bullishGNI Group
18 Oct 2018 14:10

Investment Thesis and Valuation

Key Drivers / Concerns Etuary’s inclusion in China insurance reimbursement program Stable income from recently acquired medical device...

x